Skip to main content
Image
Per Wold-Olsen
Chairman of the Board

Board member since 2023.

Born: 1947

Nationality: Norwegian

Education: MBA in Economics and Administration from Handelshøyskolen Oslo and an MBA in Management & Marketing from the University of Wisconsin.

Main employment: Board professional and advisor in the Life Science industry

Other assignments: Chairman of the board of Oncopeptides AB (publ.) and board member of Forefront Capital Partners. 

Previous assignments: Extensive experience from the life science industry and has held many senior positions for 30 years within Merck & Co, of which the last 15 years were based in the USA and part of Merck's executive leadership team. Since 2006, Per has been a member of several boards within the life science sector, including Novo Holdings, Lundbeck, Gilead Sciences, Pharmaset, Royal Dutch Numico and GN Store Nord. 

Per Wold-Olsen is independent of the company and its executive management and in relation to other major shareholders of the company.

Shareholding in Senzime: Per Wold-Olsen owns 716,344 shares in Senzime. 

Image
Adam Dahlberg
Vice Chairman of the Board

Board member since 2000.

Born: 1973

Nationality: Swedish

Education: MSc, Stockholm School of Economics.

Main employment: Investor in Life Science, new materials, and software.

Other assignments: Chairman of the board of Acuvi AB and Corline Biomedical AB.

Previous assignments: Chairman of the board of Senzime AB (publ).

Adam Dahlberg is independent of the company and its executive management but not in relation to other major shareholders of the company.

Shareholding in Senzime: Adam Dahlberg owns 6,987,664 shares of Senzime, privately and through companies. In addition, Margareta Nilsson owns 3,752,370 shares, Ebba Fischer owns 2,718,090 shares, Anna Manhusen 1,869,876 shares, AB Pethle 578,595 shares and Carl Rosenblad 487,855 shares in the company, all of which are related to Adam Dahlberg. In addition, the Crafoord Foundation owns 6,278,119 shares,

Image
Eva Walde
Board Member

Board member since 2020

Born: 1963

Nationality: Swedish

Education: MSc in Economics from the Gothenburg School of Economics.

Main employment: Board professional and advisor in the Life Science industry

Other assignments: Board member of Sedana Medical AB, FrostPharma AB, Epigenica AB, Life Science Invest Scale Up, Life Science Invest Epsilon. Chairman of the Board of Redsense Medical AB. 

Previous assignments: Over 30 years of experience in leading roles in companies such as Johnson & Johnson, Pfizer and Thermo Fisher.

Eva Walde is independent of the company and its executive management and in relation to other major shareholders of the company.

Shareholding in Senzime: 0

Image
Göran Brorsson
Board Member

Board member since 2023

Nationality: Swedish

Born: 1952

Education: MBA from Gothenburg University, International Management Program at the International Management Institute, Geneva.

Main employment: Since 2015 an independent advisor to medical technology and life science companies.

Other assignments: Chairman Suturion AB, chairman Stairway Medical, board member Albin Invest and partner Middle Branch Partner.

Previous assignments: More than 40 years of managerial experience in small and medium sized companies and big corporations in the Nordics, Europe, the US, and Asia. Göran held key leadership roles in operations, sales, manufacturing, and distribution of medical device products. Between the years 2000 and 2015, Göran Brorsson was CEO of Elos Medtech AB.

Göran Brorsson is independent of the company and its executive management and independent in relation to other major shareholders of the company.

Shareholding in Senzime:  101,500 shares

Image
Lars Axelson
Board Member

Board member since 2023.

Born: 1961

Nationality: Swedish

Education: Bachelor of Economics, Karlstad University

Main employment: CEO AB Segulah and at CFO Segulah Medical Acceleration AB

Other assignments: Chairman of the Board at Svenska Spol & Relining gruppen AB, Board Member Mönsterås Trädetaljer AB and Segulah V Investment AB.

Previous assignments: 25 years of experience as CFO, in both listed and unlisted companies, often Private Equity-backed.

Lars Axelson is independent of the company and its executive management but not in relation to other major shareholders of the company.

Shareholding in Senzime: Lars Axelson owns 91,976 shares in Senzime. Lars also has indirect control of 2,027,271 shares held by AB Segulah, 3,076,000 shares held by Segulah Venture AB and 7,700,000 shares held by Segulah Medical Acceleration AB. 

Image
Sorin J. Brull
Board member

Board member since 2016.

Born: 1956

Nationality: American

Education: Medical School, WVU, Residency (Anesthesia), Yale University, Fellowship, Yale University.

Main employment: Consultant in anesthesiology and Professor Emeritus at the Mayo Clinic College of Medicine.

Other assignments: Board member of the Anesthesia Patient Safety Foundation (APSF) and consultant to the US Food and Drug Administration (FDA).

Previous assignments: Founder of Acacia Designs B.V., which was acquired by Senzime AB in 2016. Head of Department at the University of Arkansas for Medical Sciences (UAMS) and Section Chief of the Department of Anesthesiology at Yale School of Medicine, and member of the Anesthesia Patient Safety Foundation.

Sorin J. Brull is not independent of the company and its executive management but independent in relation to other major shareholders of the company.

Shareholding in Senzime:  Sorin J. Brull owns a total of 3,770,309 shares in the company through the Pershing Trustee.